3,170 results match your criteria Congenital Muscular Dystrophy


Metreleptin treatment for congenital generalized lipodystrophy type 4 (CGL4): a case report.

Clin Pediatr Endocrinol 2019 31;28(1):1-7. Epub 2019 Jan 31.

Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan.

Congenital generalized lipodystrophy type 4 (CGL4) is a rare disease caused by mutations in the gene polymerase I and transcript release factor (), the main symptoms of which are systemic reductions in adipose tissue and muscular dystrophy. The strategy of treating CGL4 is to improve the insulin resistance and hypertriglyceridemia that result from systemic reductions in adipose tissue. Metreleptin, a synthetic analog of human leptin, is effective against generalized lipodystrophies; however, there are no reports of the use of metreleptin in the treatment of CGL4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1297/cpe.28.1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6356095PMC
January 2019
1 Read

Severe Neonatal RYR1 Myopathy With Pathological Features of Congenital Muscular Dystrophy.

J Neuropathol Exp Neurol 2019 Feb 4. Epub 2019 Feb 4.

Department of Pathology and Laboratory Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.

The phenotypes associated with pathogenic variants in the ryanodine receptor 1 gene (RYR1, OMIM# 180901) have greatly expanded over the last few decades as genetic testing for RYR1 variants has become more common. Initially described in association with malignant hyperthermia, pathogenic variants in RYR1 are typically associated with core pathology in muscle biopsies (central core disease or multiminicore disease) and symptomatic myopathies with symptoms ranging from mild weakness to perinatal lethality. We describe a 2-week-old male patient with multiple congenital dysmorphisms, severe perinatal weakness, and subsequent demise, whose histopathology on autopsy was consistent with congenital muscular dystrophy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnen/nlz004DOI Listing
February 2019
1 Read

[Clinical manifestations and genetics analysis of collagen type Ⅵ-related myopathy caused by variants in COL6A3 gene].

Zhonghua Er Ke Za Zhi 2019 Feb;57(2):136-141

Department of Neurology, Children's Hospital, Capital Institute of Pediatrics, Beijing 100020, China.

To summarize the clinical manifestations and determine the molecular etiology for two collagen type Ⅵ-related myopathy pedigrees. Two spontaneous collagen type Ⅵ-related myopathy patients were admitted to Department of Neurology, Children's Hospital, Capital Institute of Pediatrics in October 2017. Clinical data of probands and their family members were collected and their genomic DNA was obtained for genetic testing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3760/cma.j.issn.0578-1310.2019.02.014DOI Listing
February 2019
1 Read

Speckle-Tracking Echocardiography in Children With Duchenne Muscular Dystrophy: A Prospective Multicenter Controlled Cross-Sectional Study.

J Am Soc Echocardiogr 2019 Jan 21. Epub 2019 Jan 21.

PHYMEDEXP, University of Montpellier, CNRS, INSERM, CHU Montpellier, Montpellier, France.

Background: Prognosis of Duchenne muscular dystrophy (DMD) is related to cardiac dysfunction. Speckle-tracking echocardiographic (STE) imaging is emerging as a noninvasive functional biomarker to consider in the early detection of DMD-related cardiomyopathy. However, STE analysis has not been assessed in a prospectively controlled study, especially in presymptomatic children with DMD, and no study has used STE analysis in all three displacements (longitudinal, radial, and circumferential) and for both ventricles. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S08947317183060
Publisher Site
http://dx.doi.org/10.1016/j.echo.2018.10.017DOI Listing
January 2019
6 Reads
4.056 Impact Factor

Cardiac and skeletal muscle effects in the randomized HOPE-Duchenne trial.

Neurology 2019 Feb 23;92(8):e866-e878. Epub 2019 Jan 23.

From The Heart Institute (M.T., J.J., B.G.), Cincinnati Children's Hospital Medical Center, OH; Department of Pediatrics and Molecular Genetics and Microbiology, Powell Gene Therapy Center (B.B.), and Division of Pediatric Cardiology, Congenital Heart Center (J.F.), University of Florida, Gainesville; Department of Cardiology (J.L., B.A.-V., M.R.O.), Johns Hopkins University, Baltimore, MD; Smidt Heart Institute (R.M., E.M., R.G.V.), Cedars-Sinai Medical Center, Los Angeles, CA; Capricor Therapeutics (R.R.S., B.F., J.R., J.M.P., L.M., D.D.A.), Beverly Hills, CA; and Department of Cardiology (K.M.), Laikon Hospital, Athens, Greece.

Objective: To assess the feasibility, safety, and efficacy of intracoronary allogeneic cardiosphere-derived cells (CAP-1002) in patients with Duchenne muscular dystrophy (DMD).

Methods: The Halt Cardiomyopathy Progression (HOPE)-Duchenne trial is a phase I/II, randomized, controlled, open-label trial (NCT02485938). Patients with DMD >12 years old, with substantial myocardial fibrosis, were randomized (1:1) to usual care (control) or global intracoronary infusion of CAP-1002 (75 million cells). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000006950DOI Listing
February 2019
1 Read

A Nationwide, Population-Based Prevalence Study of Genetic Muscle Disorders.

Neuroepidemiology 2019 Jan 18;52(3-4):128-135. Epub 2019 Jan 18.

Department of Neurology, Auckland City Hospital, Auckland, New Zealand.

Background: Previous epidemiological studies of genetic muscle disorders have relied on medical records to identify cases and may be at risk of selection biases or have focused on selective population groups.

Objectives: This study aimed to determine age-standardised prevalence of genetic muscle disorders through a nationwide, epidemiological study across the lifespan using the capture-recapture method.

Methods: Adults and children with a confirmed clinical or molecular diagnosis of a genetic muscle disorder, resident in New Zealand on April 1, 2015 were identified using multiple overlapping sources. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000494115DOI Listing
January 2019
1 Read

Mammalian O-mannosyl glycans: Biochemistry and glycopathology.

Authors:
Tamao Endo

Proc Jpn Acad Ser B Phys Biol Sci 2019 ;95(1):39-51

Tokyo Metropolitan Institute of Gerontology.

Glycosylation is an important posttranslational modification in mammals. The glycans of glycoproteins are classified into two groups, namely, N-glycans and O-glycans, according to their glycan-peptide linkage regions. Recently, O-mannosyl glycan, an O-glycan, has been shown to be important in muscle and brain development. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2183/pjab.95.004DOI Listing
January 2019

Characteristic clinical and ultrastructural findings in nesprinopathies.

Eur J Paediatr Neurol 2018 Dec 29. Epub 2018 Dec 29.

Department of Pediatric Neurology, Developmental Neurology and Social Pediatrics, University of Essen, Germany.

Aims: To define the neurological and neuropathological alterations caused by SYNE1 mutations.

Methods: We describe 5 patients (3 males, 2 females; age 3-24 years) from 3 families. The diagnostic work-up included three muscle biopsies and two nerve biopsies in three of the cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejpn.2018.12.011DOI Listing
December 2018
3 Reads

Chromosomal Microarray Analysis as a First-Tier Clinical Diagnostic Test in Patients With Developmental Delay/Intellectual Disability, Autism Spectrum Disorders, and Multiple Congenital Anomalies: A Prospective Multicenter Study in Korea.

Ann Lab Med 2019 May;39(3):299-310

Department of Rehabilitation Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Background: To validate the clinical application of chromosomal microarray analysis (CMA) as a first-tier clinical diagnostic test and to determine the impact of CMA results on patient clinical management, we conducted a multicenter prospective study in Korean patients diagnosed as having developmental delay/intellectual disability (DD/ID), autism spectrum disorders (ASD), and multiple congenital anomalies (MCA).

Methods: We performed both CMA and G-banding cytogenetics as the first-tier tests in 617 patients. To determine whether the CMA results directly influenced treatment recommendations, the referring clinicians were asked to complete a 39-item questionnaire for each patient separately after receiving the CMA results. Read More

View Article

Download full-text PDF

Source
https://synapse.koreamed.org/DOIx.php?id=10.3343/alm.2019.39
Publisher Site
http://dx.doi.org/10.3343/alm.2019.39.3.299DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6340852PMC
May 2019
5 Reads
1.481 Impact Factor

Congenital myopathy with a novel SELN missense mutation and the challenge to differentiate it from congenital muscular dystrophy.

J Clin Neurosci 2019 Jan 3. Epub 2019 Jan 3.

Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA.

Multiminicore disease is a myopathy that is pathologically characterized by the presence of multiple areas of small, short, and poorly delineated zones of sarcomeric disorganization lacking mitochondria (minicores) that can be observed in both type 1 and type 2 fibers. Most cases of multiminicore disease typically present with early-onset axial weakness, respiratory insufficiency, scoliosis, and rigid spine. There is no correlation between the frequency of minicores and clinical severity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jocn.2018.12.024DOI Listing
January 2019

RGD inhibition of itgb1 ameliorates laminin-a2 deficient zebrafish fibre pathology.

Hum Mol Genet 2018 Dec 19. Epub 2018 Dec 19.

Australian Regenerative Medicine Institute, Monash University, 15, Innovation Walk, Clayton Campus, Wellington Road, Clayton, Victoria, Australia, VIC 3800.

Deficiency of muscle basement membrane (MBM) component laminin-α2, leads to muscular dystrophy congenital type 1a MDC1a, a currently untreatable myopathy. Laminin-α2 has two main binding partners within the MBM, dystroglycan and integrin. Integrins co-ordinate both cell adhesion and signalling, however there is little mechanistic insight into integrin's function at the MBM. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/hmg/advance-article/doi/10.1093/hmg
Publisher Site
http://dx.doi.org/10.1093/hmg/ddy426DOI Listing
December 2018
7 Reads

Primary muscle involvement in a 15-year-old girl with the recurrent homozygous c.362dupC variant in FKBP14.

Am J Med Genet A 2019 Feb 18;179(2):317-321. Epub 2018 Dec 18.

Division of Neuromuscular and Neurodegenerative Disorders, IRCCS-Bambino Gesù Children's Hospital, Rome, Italy.

Kyphoscoliotic Ehlers-Danlos syndrome associated with FKBP14 (FKBP14-kEDS) is an ultrarare autosomal recessive disorder reported in less than 30 individuals so far. In its original description, emphasis was put on the mild muscle involvement. Further reports confirm that FKBP14-kEDS is distinguishable from primary muscle disorders by the lack of progressive muscle disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajmg.a.61006DOI Listing
February 2019
1 Read

LARGE expression in different types of muscular dystrophies other than dystroglycanopathy.

BMC Neurol 2018 Dec 15;18(1):207. Epub 2018 Dec 15.

Department of Medical Biology, Hacettepe University Faculty of Medicine, 06100 Sihhiye, Ankara, Turkey.

Background: Alpha-dystroglycan (αDG) is an extracellular peripheral glycoprotein that acts as a receptor for both extracellular matrix proteins containing laminin globular domains and certain arenaviruses. An important enzyme, known as Like-acetylglucosaminyltransferase (LARGE), has been shown to transfer repeating units of -glucuronic acid-β1,3-xylose-α1,3- (matriglycan) to αDG that is required for functional receptor as an extracellular matrix protein scaffold. The reduction in the amount of LARGE-dependent matriglycan result in heterogeneous forms of dystroglycanopathy that is associated with hypoglycosylation of αDG and a consequent lack of ligand-binding activity. Read More

View Article

Download full-text PDF

Source
https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-
Publisher Site
http://dx.doi.org/10.1186/s12883-018-1207-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295086PMC
December 2018
14 Reads

Cardiac Involvement in Emery-Dreifuss Muscular Dystrophy and Related Management Strategies.

Int Heart J 2019 Jan 5;60(1):12-18. Epub 2018 Dec 5.

Department of Cardiovascular Medicine, Second Xiangya Hospital of Central South University.

Emery-Dreifuss muscular dystrophy (EDMD) is a group of hereditary muscular dystrophy syndrome caused by deficiency of genes encoding nuclear envelope proteins. Patients having EDMD show the triad of muscle dystrophy, joint contracture, and cardiac disease. In almost all patients, cardiac involvement is prevalent and is the most severe aspect of EDMD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1536/ihj.17-604DOI Listing
January 2019
1 Read

Targeted next generation sequencing reveals novel splice site mutations in gene in a patient with congenital muscular dystrophy.

Neurol India 2018 Nov-Dec;66(6):1812-1814

Diagnostics Division, Centre for DNA Fingerprinting and Diagnostics, Telangana, India.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/0028-3886.246266DOI Listing
December 2018
4 Reads

Recessive PYROXD1 mutations cause adult-onset limb-girdle-type muscular dystrophy.

J Neurol 2019 Feb 4;266(2):353-360. Epub 2018 Dec 4.

Research Programs Unit, Molecular Neurology, University of Helsinki, Helsinki, Finland.

Objective: To describe adult-onset limb-girdle-type muscular dystrophy caused by biallelic variants in the PYROXD1 gene, which has been recently linked to early-onset congenital myofibrillar myopathy.

Methods: Whole exome sequencing was performed for adult-onset neuromuscular disease patients with no molecular diagnosis. Patients with PYROXD1 variants underwent clinical characterization, lower limb muscle MRI, muscle biopsy and spirometry. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00415-018-9137-8
Publisher Site
http://dx.doi.org/10.1007/s00415-018-9137-8DOI Listing
February 2019
14 Reads
3.380 Impact Factor

Spontaneous Spongiform Brainstem Degeneration in a Young Mouse Lemur (Microcebus murinus) with Conspicuous Behavioral, Motor, Growth, and Ocular Pathologies.

Comp Med 2018 Nov 28. Epub 2018 Nov 28.

Here we report a case of severe growth retardation and neurologic abnormalities in a female gray mouse lemur (Microcebusmurinus), a small NHP species for which the genomic sequence recently became available. The female lemur we present heredied on postnatal day 125. This lemur had impaired development of motor skills and showed severe ataxia and tremors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.30802/AALAS-CM-18-000019DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310204PMC
November 2018
2 Reads

Emergency room visits and admission rates of children with neuromuscular disorders: A 10-year experience in a medical center in Taiwan.

Pediatr Neonatol 2018 Oct 2. Epub 2018 Oct 2.

Division of Pediatric Emergency, Department of Emergency, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; Ph.D. Program in Translational Medicine, Graduate Institute of Clinical Medicine, 18 Kaohsiung Medical University and Academia Sinica, Taiwan; Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. Electronic address:

Background: No previous studies have explored emergency medical care for children with chronic neuromuscular disorders (NMDs). We aimed to determine the major reasons for the emergency room (ER) readmission of pediatric patients with NMDs and suggest changes to the care plan to decrease readmissions.

Methods: Children with chronic NMDs (aged <18 years) who visited a medical center-based ER between January 2005 and January 2015 were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pedneo.2018.09.008DOI Listing
October 2018
4 Reads
0.880 Impact Factor

Molecular genetics of the POMT1-related muscular dystrophy-dystroglycanopathies.

Mutat Res 2018 Oct - Dec;778:45-50. Epub 2018 Sep 12.

Center for Experimental Medicine, the Third Xiangya Hospital, Central South University, Changsha, PR China. Electronic address:

Protein O-mannosyltransferase 1 (POMT1) is a critical enzyme participating in the first step of protein O-mannosylation. Mutations in the coding gene, POMT1, have been described to be related to a series of autosomal recessive disorders associated with defective alpha-dystroglycan glycosylation, later termed muscular dystrophy-dystroglycanopathies (MDDGs). MDDGs are characterized by a broad phenotypic spectrum of congenital muscular dystrophy or later-onset limb-girdle muscular dystrophy, accompanied by variable degrees of intellectual disability, brain defects, and ocular abnormalities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mrrev.2018.09.002DOI Listing
September 2018
9 Reads

Exploratory Profiling of Urine MicroRNAs in the Mouse Model of LAMA2-CMD: Relation to Disease Progression.

PLoS Curr 2018 Aug 27;10. Epub 2018 Aug 27.

Integrative Biology and Physiology, University of California, Los Angeles, California, United States.

Circulating microRNAs (miRNAs) are being considered as non-invasive biomarkers for disease progression and clinical trials. Congenital muscular dystrophy with deficiency of laminin α2 chain (LAMA2-CMD) is a very severe form of muscular dystrophy, for which no treatment is available. In order to identify LAMA2-CMD biomarkers we have profiled miRNAs in urine from the / mouse model of LAMA2-CMD at three distinct time points (representing asymptomatic, initial and established disease). Read More

View Article

Download full-text PDF

Source
https://dx.plos.org/10.1371/currents.md.d0c203c018bc024f2f4c
Publisher Site
http://dx.doi.org/10.1371/currents.md.d0c203c018bc024f2f4c9791ecb05f88DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140833PMC
August 2018
7 Reads

Cervical hyperextension deformity following sagittal balance correction in a patient with Congenital Limb Girdle Myopathy: Surgical technique and review of the literature.

World Neurosurg 2018 Nov 8. Epub 2018 Nov 8.

- Neurosurgery department, Hotel Dieu de France Hospital Beirut, Lebanon. Electronic address:

Background: There is no gold standard surgical treatment for cervical hyperextension deformity especially in case of muscular dystrophy. Special considerations and caution should be taken as they carry high risk of early mortality and spinal cord injury. Only a few case reports are available in the literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.wneu.2018.10.211DOI Listing
November 2018
1 Read

Needle electromyography and histopathologic correlation in myopathies.

Muscle Nerve 2019 Mar 29;59(3):315-320. Epub 2018 Dec 29.

Mayo Clinic Neurology Department, 4500 San Pablo Road South, Jacksonville, Florida, 32224, USA.

Introduction: Needle electromyography (EMG) findings help confirm myopathy and may indicate specific pathologic changes on muscle biopsy.

Methods: We conducted a retrospective chart review of 218 consecutive patients referred for muscle biopsy. Presence of specific needle EMG findings was correlated with pathologic findings of inflammation, necrosis, splitting, and vacuolar changes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mus.26381DOI Listing
March 2019
1 Read

Modeling Skeletal Muscle Laminopathies Using Human Induced Pluripotent Stem Cells Carrying Pathogenic Mutations.

Front Physiol 2018 15;9:1332. Epub 2018 Oct 15.

Department of Cell and Developmental Biology, University College London, London, United Kingdom.

Laminopathies are a clinically heterogeneous group of disorders caused by mutations in . The main proteins encoded by are Lamin A and C, which together with Lamin B1 and B2, form the nuclear lamina: a mesh-like structure located underneath the inner nuclear membrane. Laminopathies show striking tissue specificity, with subtypes affecting striated muscle, peripheral nerve, and adipose tissue, while others cause multisystem disease with accelerated aging. Read More

View Article

Download full-text PDF

Source
https://www.frontiersin.org/article/10.3389/fphys.2018.01332
Publisher Site
http://dx.doi.org/10.3389/fphys.2018.01332DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201196PMC
October 2018
7 Reads

Effects of metformin on congenital muscular dystrophy type 1A disease progression in mice: a gender impact study.

Sci Rep 2018 Nov 2;8(1):16302. Epub 2018 Nov 2.

Unit of Muscle Biology, Department of Experimental Medical Science, Lund University, Lund, Sweden.

Congenital muscular dystrophy with laminin α2 chain-deficiency (LAMA2-CMD) is a severe muscle disorder with complex underlying pathogenesis. We have previously employed profiling techniques to elucidate molecular patterns and demonstrated significant metabolic impairment in skeletal muscle from LAMA2-CMD patients and mouse models. Thus, we hypothesize that skeletal muscle metabolism may be a promising pharmacological target to improve muscle function in LAMA2-CMD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-34362-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214987PMC
November 2018

Myotonic Dystrophies: Targeting Therapies for Multisystem Disease.

Neurotherapeutics 2018 10;15(4):872-884

Department of Neurology, The Ohio State University, 395 West 12th Avenue, Columbus, OH, 43210, USA.

Myotonic dystrophy is an autosomal dominant muscular dystrophy not only associated with muscle weakness, atrophy, and myotonia but also prominent multisystem involvement. There are 2 similar, but distinct, forms of myotonic dystrophy; type 1 is caused by a CTG repeat expansion in the DMPK gene, and type 2 is caused by a CCTG repeat expansion in the CNBP gene. Type 1 is associated with distal limb, neck flexor, and bulbar weakness and results in different phenotypic subtypes with variable onset from congenital to very late-onset as well as variable signs and symptoms. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s13311-018-00679-z
Publisher Site
http://dx.doi.org/10.1007/s13311-018-00679-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277298PMC
October 2018
20 Reads

Activation of the interferon type I response rather than autophagy contributes to myogenesis inhibition in congenital DM1 myoblasts.

Cell Death Dis 2018 Oct 19;9(11):1071. Epub 2018 Oct 19.

Institute of Biophysics (IBF), CNR, Pisa, Italy.

Congenital myotonic dystrophy type 1 (CDM1) is characterized by severe symptoms that affect patients from birth, with 40% mortality in the neonatal period and impaired skeletal muscle development. In this paper, we examined the relationship between autophagy and abnormal myogenic differentiation of CDM1 myoblasts. We investigated these pathological features at both ultrastructural and molecular levels, utilizing two CDM1 foetal myoblasts, CDM13 and CDM15, with 1800 and 3200 repeats, respectively. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41419-018-1080-1
Publisher Site
http://dx.doi.org/10.1038/s41419-018-1080-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6195593PMC
October 2018
12 Reads

Commentary on "Stepping Activity in Children With Congenital Myotonic Dystrophy".

Pediatr Phys Ther 2018 10;30(4):340

Department of Pediatrics, University of Massachusetts Medical School Worcester, Massachusetts School of Health and Rehabilitation Sciences, MGH Institute of Health Professions Boston, Massachusetts.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PEP.0000000000000545DOI Listing
October 2018

Stepping Activity in Children With Congenital Myotonic Dystrophy.

Pediatr Phys Ther 2018 10;30(4):335-339

Department of Physical Therapy and Athletic Training (Dr Hayes) and Department of Neurology (Mss Dibella and Crockett and Drs Dixon, Butterfield, and Johnson), University of Utah, Salt Lake City, Utah.

Purpose: The purpose of this study was to investigate the physical activity levels in children with congenital myotonic dystrophy (CDM), and to examine whether patient clinical and functional characteristics correlated to physical activity.

Methods: Twenty-five children with CDM were assessed on functional measures, clinical measures, and physical activity levels.

Results: Results support that children with CDM spend the majority of their time inactive. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PEP.0000000000000537DOI Listing
October 2018

Birth Anomalies in Monozygotic and Dizygotic Twins: Results From the California Twin Registry.

J Epidemiol 2019 Jan 29;29(1):18-25. Epub 2018 Sep 29.

Department of Preventive Medicine, Keck School of Medicine, University of Southern California.

Background: Inherited factors and maternal behaviors are thought to play an important role in the etiology of several congenital malformations. Twin studies can offer additional evidence regarding the contribution of genetic and lifestyle factors to common birth anomalies, but few large-scale studies have been reported.

Methods: We included data from twins (20,803 pairs) from the population-based California Twin Program. Read More

View Article

Download full-text PDF

Source
https://www.jstage.jst.go.jp/article/jea/advpub/0/advpub_JE2
Publisher Site
http://dx.doi.org/10.2188/jea.JE20170159DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290277PMC
January 2019
3 Reads

Broad phenotypic spectrum and genotype-phenotype correlations in GMPPB-related dystroglycanopathies: an Italian cross-sectional study.

Orphanet J Rare Dis 2018 Sep 26;13(1):170. Epub 2018 Sep 26.

Department of Developmental Neuroscience and Molecular Medicine Neuromuscular Unit and Child Neurology, IRCCS Fondazione Stella Maris, Via dei Giacinti 2, 56018, Pisa, Italy.

Background: Dystroglycanopathy (α-DG) is a relatively common, clinically and genetically heterogeneous category of congenital forms of muscular dystrophy (CMD) and limb-girdle muscular dystrophy (LGMD) associated with hypoglycosylated α-dystroglycan. To date, mutations in at least 19 genes have been associated with α-DG. One of them, GMPPB, encoding the guanosine-diphosphate-mannose (GDP-mannose) pyrophosphorylase B protein, has recently been associated with a wide clinical spectrum ranging from severe Walker-Warburg syndrome to pseudo-metabolic myopathy and even congenital myasthenic syndromes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13023-018-0863-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158856PMC
September 2018
11 Reads

National registry of patients with Fukuyama congenital muscular dystrophy in Japan.

Neuromuscul Disord 2018 Oct 10;28(10):885-893. Epub 2018 Aug 10.

Department of Pediatrics, Tokyo Women's Medical University, School of Medicine, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan; The Japan Muscular Dystrophy Association, Tokyo, Japan.

Fukuyama congenital muscular dystrophy (FCMD) is the second most common form of muscular dystrophy in the Japanese population and is caused by mutations in the fukutin (FKTN) gene. In 2011, the Japan Muscular Dystrophy Association (JMDA) developed a nationwide registry of genetically confirmed patients with FCMD. We retrospectively reviewed the registry dataset of patients with FCMD to obtain data, including age, sex, developmental milestones, intellectual level, complications, and primary treatments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nmd.2018.08.001DOI Listing
October 2018
4 Reads
2.640 Impact Factor

[Clinical features and FKRP mutations of congenital muscular dystrophy 1C].

Zhongguo Dang Dai Er Ke Za Zhi 2018 Sep;20(9):765-768

Department of Pediatrics, Union Hospital Affiliated to Fujian Medical University, Fuzhou 350001, China.

Congenital muscular dystrophy type 1C (MDC1C) is caused by the homozygous or compound heterozygous mutations of the FKRP gene. This article reported the clinical and mutation features of a child with MDC1C. The boy aged 8 months visited the hospital due to delayed development. Read More

View Article

Download full-text PDF

Source
September 2018
5 Reads

Myofibrillar myopathy in the genomic context.

J Appl Genet 2018 Nov 10;59(4):431-439. Epub 2018 Sep 10.

Department of Neurodegenerative Disorders, Mossakowski Medical Research Centre, Polish Academy of Sciences, 5 Pawinskiego St., 02-106, Warsaw, Poland.

Myofibrillar myopathy (MFM) is a group of inherited muscular disorders characterized by myofibril dissolution and abnormal accumulation of degradation products. The diagnosis of muscular disorders based on clinical presentation is difficult due to phenotypic heterogeneity and overlapping symptoms. In addition, precise diagnosis does not always explain the disease etiopathology or the highly variable clinical course even among patients diagnosed with the same type of myopathy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13353-018-0463-4DOI Listing
November 2018
2 Reads

Characteristic findings of skeletal muscle MRI in caveolinopathies.

Neuromuscul Disord 2018 Oct 31;28(10):857-862. Epub 2018 Jul 31.

Department of Pediatrics, School of Medicine, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, Japan. Electronic address:

Caveolinopathies, caused by CAV3 mutations, can include several phenotypes such as rippling muscle disease, limb-girdle muscular dystrophy type 1C, distal myopathy, familial hypertrophic cardiomyopathy, and idiopathic hyperCKemia. Here we present characteristic skeletal muscle imaging findings in four patients with genetically defined childhood-onset RMD caused by CAV3 mutations and in one patient with congenital generalized lipodystrophy type 4 with muscular dystrophy due to polymerase I and transcript release factor (PTRF) mutations, which may have caused secondary deficiency of caveolin-3. Muscle MRI revealed that the rectus femoris and semitendinosus muscles were most commonly affected in the rippling muscle disease patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nmd.2018.07.010DOI Listing
October 2018
7 Reads
2.640 Impact Factor

Exon Skipping Using Antisense Oligonucleotides for Laminin-Alpha2-Deficient Muscular Dystrophy.

Methods Mol Biol 2018 ;1828:553-564

Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Japan.

Phosphorodiamidate morpholino oligomer (PMO)-mediated exon skipping is among the more promising approaches available for the treatment of several neuromuscular disorders, including Duchenne muscular dystrophy. The main weakness of this treatment arises from the low efficiency and sporadic nature of delivery of the neutrally charged PMO into muscle fibers, the mechanism of which is unknown.Recently, using wild-type and dystrophic mdx52 mice, we showed that muscle fibers took up PMO more efficiently during myotube formation. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/978-1-4939-8651-4_36
Publisher Site
http://dx.doi.org/10.1007/978-1-4939-8651-4_36DOI Listing
January 2018
12 Reads

Restoration of Dystrophin Protein Expression by Exon Skipping Utilizing CRISPR-Cas9 in Myoblasts Derived from DMD Patient iPS Cells.

Methods Mol Biol 2018 ;1828:191-217

Center for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.

Duchenne muscular dystrophy (DMD) is a congenital X-linked disease caused by mutations in the gene encoding the dystrophin protein, which is required for myofiber integrity. Exon skipping therapy is an emerging strategy for restoring the open reading frame of the dystrophin gene to produce functional protein in DMD patients by skipping single or multiple exons. Although antisense oligonucleotides are able to target pre-mRNA for exon skipping, their half-lives are short and any therapeutic benefit is transient. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/978-1-4939-8651-4_12
Publisher Site
http://dx.doi.org/10.1007/978-1-4939-8651-4_12DOI Listing
January 2018
22 Reads

Tips to Design Effective Splice-Switching Antisense Oligonucleotides for Exon Skipping and Exon Inclusion.

Methods Mol Biol 2018 ;1828:79-90

Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada.

Antisense-mediated exon skipping and exon inclusion have proven to be powerful tools for treating neuromuscular diseases. The approval of Exondys 51 (eteplirsen) and Spinraza (nusinersen) for the treatment of patients with Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA) was the most noteworthy accomplishment in 2016. Exon skipping uses short DNA-like molecules called antisense oligonucleotides (AONs) to correct the disrupted reading frame, allowing the production of functional quasi-dystrophin proteins, and ameliorate the progression of the disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-8651-4_5DOI Listing
January 2018
3 Reads

An Overview of Recent Advances and Clinical Applications of Exon Skipping and Splice Modulation for Muscular Dystrophy and Various Genetic Diseases.

Methods Mol Biol 2018 ;1828:31-55

Department of Medical Genetics, University of Alberta Faculty of Medicine and Dentistry, Edmonton, AB, Canada.

Exon skipping is a therapeutic approach that is feasible for various genetic diseases and has been studied and developed for over two decades. This approach uses antisense oligonucleotides (AON) to modify the splicing of pre-mRNA to correct the mutation responsible for a disease, or to suppress a particular gene expression, as in allergic diseases. Antisense-mediated exon skipping is most extensively studied in Duchenne muscular dystrophy (DMD) and has developed from in vitro proof-of-concept studies to clinical trials targeting various single exons such as exon 45 (casimersen), exon 53 (NS-065/NCNP-01, golodirsen), and exon 51 (eteplirsen). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4939-8651-4_2DOI Listing
January 2018
6 Reads

STAC3 variants cause a congenital myopathy with distinctive dysmorphic features and malignant hyperthermia susceptibility.

Hum Mutat 2018 Dec 11;39(12):1980-1994. Epub 2018 Oct 11.

Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health, London, UK.

SH3 and cysteine-rich domain-containing protein 3 (STAC3) is an essential component of the skeletal muscle excitation-contraction coupling (ECC) machinery, though its role and function are not yet completely understood. Here, we report 18 patients carrying a homozygous p.(Trp284Ser) STAC3 variant in addition to a patient compound heterozygous for the p. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/humu.23635
Publisher Site
http://dx.doi.org/10.1002/humu.23635DOI Listing
December 2018
9 Reads

Ribitol restores functionally glycosylated α-dystroglycan and improves muscle function in dystrophic FKRP-mutant mice.

Nat Commun 2018 08 27;9(1):3448. Epub 2018 Aug 27.

McColl-Lockwood Laboratory for Muscular Dystrophy Research, Cannon Research Center, Carolinas Medical Center, Carolinas Healthcare System, Charlotte, NC, 28203, USA.

O-mannosylated α-dystroglycan (α-DG) serves as receptors for cell-cell and cell-extracellular matrix adhesion and signaling. Hypoglycosylation of α-DG is involved in cancer progression and underlies dystroglycanopathy with aberrant neuronal development. Here we report that ribitol, a pentose alcohol with previously unknown function in mammalian cells, partially restores functional O-mannosylation of α-DG (F-α-DG) in the dystroglycanopathy model containing a P448L mutation in fukutin-related protein (FKRP) gene, which is clinically associated with severe congenital muscular dystrophy. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41467-018-05990-z
Publisher Site
http://dx.doi.org/10.1038/s41467-018-05990-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110760PMC
August 2018
12 Reads

LAMA2 Congenital Muscle Dystrophy: A Novel Pathogenic Mutation in Bulgarian Patient.

Case Rep Genet 2018 25;2018:3028145. Epub 2018 Jul 25.

Laboratory of Genomic Diagnostics, Center of Molecular Medicine, Department of Medical Chemistry and Biochemistry, Medical University Sofia, Zdrave Str. 2, 1431 Sofia, Bulgaria.

Congenital muscle dystrophies (CMD) are genetically and clinically heterogeneous hereditary myopathies mainly with autosomal recessive type of inheritance. The most common form worldwide is considered to be merosin-deficient muscle dystrophy type 1A, called MDC1A (due to laminin-2 defects as a result of gene mutation), accounting for 30-40% of total cases of CMD. The exact molecular and clinical diagnoses, respectively, are a prerequisite for the most effective treatment; sometimes orphan drugs exist for some rare diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/3028145DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6083551PMC
July 2018
1 Read

Steroid therapy in an alpha-dystroglycanopathy due to GMPPB gene mutations: A case report.

Neuromuscul Disord 2018 Nov 19;28(11):956-960. Epub 2018 Jul 19.

Department of Translational Medical Sciences, Federico II University, Naples, Italy; Telethon Institute of Genetics and Medicine, Pozzuoli, Italy. Electronic address:

Alpha-dystroglycanopathies are a group of progressive and untreatable neuromuscular disorders, due to aberrant alpha-dystroglycan glycosylation. We describe the effects of a short-term cycle of corticosteroid therapy in a 9-year-old boy, affected by an alpha-dystroglycanopathy due to GMPPB gene mutations. The patient was affected by a congenital progressive muscular dystrophy since the first month of life, associated with psychomotor delay, seizures, and congenital bilateral cataracts. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09608966183050
Publisher Site
http://dx.doi.org/10.1016/j.nmd.2018.07.001DOI Listing
November 2018
10 Reads

Prediction of postnatal developmental disabilities using the antenatal fetal neurodevelopmental test: KANET assessment.

J Perinat Med 2018 Dec;47(1):77-81

Department of Pediatrics, Kagawa University Graduate School of Medicine, Miki, Kagawa, Japan.

Objective To assess the usefulness of the antenatal fetal neurodevelopmental test for the prediction of postnatal developmental disabilities. Methods Fetal behavior was assessed with Kurjak's antenatal neurodevelopmental test (KANET) using four-dimensional ultrasound between 28 and 38 weeks of gestation. A score range of 0-5 was characterized as abnormal, from 6 to 9 was considered borderline, and 10-16 was normal. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1515/jpm-2018-0169DOI Listing
December 2018
9 Reads

Respiratory insight to congenital muscular dystrophies and congenital myopathies and its relation to clinical trial.

Neuromuscul Disord 2018 Sep 1;28(9):731-740. Epub 2018 Jul 1.

Pediatric noninvasive ventilation and sleep unit, Necker university hospital, AP-HP, 149 rue de Sèvres, 75015 Paris, France; ASV Santé, Gennevilliers, France.

Congenital muscular dystrophies and congenital myopathies represent a heterogeneous group of disorders of the muscle characterized by an early onset of hypotonia and muscle weakness and consequently, a high respiratory morbidity and mortality. The diagnosis and characterization of the weakness of the respiratory muscles is crucial for clinical management of patients and the evaluation of innovative therapies. Routine respiratory evaluation is based on noninvasive volitional tests, such as the measurement of lung volumes, spirometry, and maximal static pressures, which may be difficult or impossible to obtain in young children. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09608966183012
Publisher Site
http://dx.doi.org/10.1016/j.nmd.2018.06.013DOI Listing
September 2018
6 Reads

A novel mutation identified in a Japanese patient with LMNA-associated congenital muscular dystrophy.

Hum Genome Var 2018 20;5:19. Epub 2018 Jul 20.

2Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan.

LMNA-associated congenital muscular dystrophy (L-CMD) is a severe form of muscle laminopathy. encodes lamin A, which an intermediate filament protein that attaches to the inner membrane of the nuclear envelope. We performed sequence analysis based on our original targeted gene panel system for muscle diseases to obtain a molecular diagnosis in a Japanese girl with L-CMD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41439-018-0018-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6054619PMC
July 2018
1 Read

Renal dysfunction is rare in Fukuyama congenital muscular dystrophy.

Brain Dev 2019 Jan 1;41(1):43-49. Epub 2018 Aug 1.

Department of Pediatrics, Tokyo Women's Medical University, School of Medicine, Tokyo, Japan.

Background: The leading cause of death in patients with Fukuyama congenital muscular dystrophy (FCMD) is congestive heart failure or respiratory dysfunction, which is same as that in Duchenne muscular dystrophy (DMD). Recent studies reported that renal dysfunction is a common complication and an increasing cause of death in advanced DMD. It can be attributable to circulatory instability or inappropriate use of drugs for treating cardiac dysfunction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.braindev.2018.07.012DOI Listing
January 2019
6 Reads

Muscle imaging in laminopathies: Synthesis study identifies meaningful muscles for follow-up.

Muscle Nerve 2018 Dec 18;58(6):812-817. Epub 2018 Nov 18.

APHP, Neuromuscular Disorders Unit, Pediatric Department, CHU Paris IdF Ouest - Hôpital Raymond Poincaré, Paris Saclay Universities, UVSQ University of Versailles, UMR 1179 INSERM, Garches, France.

Introduction: Particular fibroadipose infiltration patterns have been recently described by muscle imaging in congenital and later onset forms of LMNA-related muscular dystrophies (LMNA-RD).

Methods: Scores for fibroadipose infiltration of 23 lower limb muscles in 34 patients with LMNA-RD were collected from heat maps of 2 previous studies. Scoring systems were homogenized. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/mus.26312
Publisher Site
http://dx.doi.org/10.1002/mus.26312DOI Listing
December 2018
10 Reads

Long term history of a congenital core-rod myopathy with compound heterozygous mutations in the Nebulin gene.

Acta Myol 2018 Jun 1;37(2):121-127. Epub 2018 Jun 1.

Department of Pediatrics, University Hospital Cologne, 50937 Cologne, Germany.

Mutations in the Nebulin gene (NEB) may cause core-rod myopathy. The large size of the gene so far prevented inclusion of its routine analysis by didesoxy resequencing methodology in the diagnostic regime for muscular dystrophy cases. Here we report a 54-year-old female with a rare histological myopathy presentation of co-occurring cores and rods. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6060425PMC